research use only
Cat.No.S7619
| Related Targets | HDAC JAK BET PKC PARP HIF PRMT EZH2 AMPK Histone Acetyltransferase |
|---|---|
| Other Histone Methyltransferase Inhibitors | Pinometostat (EPZ5676) 3-Deazaneplanocin A (DZNep) Hydrochloride BIX-01294 trihydrochloride EPZ015666 (GSK3235025) UNC1999 EPZ004777 MM-102 (HMTase Inhibitor IX) Chaetocin SGC 0946 EPZ005687 |
|
In vitro |
DMSO
: 19 mg/mL
(50.59 mM)
Ethanol : 19 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 375.55 | Formula | C18H25N5S2 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1271738-59-0 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CC(C)C1=CC2=C(N=CN=C2S1)N3CCN(CC3)C4=NCC(C)(C)S4 | ||
| Targets/IC50/Ki |
Menin-MLL interaction
648 nM
|
|---|---|
| In vitro |
In HEK293 cells, MI-3 (Menin-MLL Inhibitor) accesses the protein target and effectively inhibits the menin-MLL-AF9 interaction. It effectively blocks MLL fusion protein-mediated leukemic transformation by downregulating the expression of target genes required for MLL fusion protein oncogenic activity. In human MLL leukemia cell lines harboring different MLL translocations, this compound effectively blocks cell proliferation and induces apoptosis.
|
| Kinase Assay |
High Throughput Screening
|
|
MI-3 (Menin-MLL Inhibitor) is screened as follows: FITC-MBM1 at 15 nM and menin at 150 nM in the FP buffer are mixed and incubated for 1h in the dark at room temperature. For point screening, 0.2 μL of each compound (20 μM final concentration, 1% DMSO) is added to 20 μL of the aliquot of the protein-peptide mixture and incubated on 384-well plates in the dark at room temperature for 1h. In confirmation screening, the serial dilution plates with this compound in DMSO are prepared and used to titrate the menin-FITC-MBM1 complex. Change in fluorescence polarization is monitored at 525 nm after excitations at 495 nm using the PHERAstar microplate reader (BMG) and applied to determine IC50 values with the Origin 7.0 program.
|
References |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05322395 | Recruiting | Acute Coronary Syndrome|Troponin|Chest Pain|Point-of-care Systems |
Liverpool University Hospitals NHS Foundation Trust|northwest coast academic science network|Quidel Corporation|Siemens Corporation Corporate Technology|Abbott Diagnostics Division |
December 10 2021 | Not Applicable |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.